Copyright © 2010 Yongqun He et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. R. Rappuoli, “Reverse vaccinology,” Current Opinion in Microbiology, vol. 3, no. 5, pp. 445–450, 2000. View at Publisher · View at Google Scholar · View at Scopus
2. M. Pizza, V. Scarlato, V. Masignani, et al., “Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing,” Science, vol. 287, no. 5459, pp. 1816–1820, 2000. View at Publisher · View at Google Scholar · View at Scopus
3. N. Ariel, A. Zvi, and A. Zvi, “Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening,” Infection and Immunity, vol. 70, no. 12, pp. 6817–6827, 2002. View at Publisher · View at Google Scholar · View at Scopus
4. B. C. Ross, L. Czajkowski, and L. Czajkowski, “Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis,” Vaccine, vol. 19, no. 30, pp. 4135–4142, 2001. View at Publisher · View at Google Scholar · View at Scopus
5. S. Montigiani, F. Falugi, and F. Falugi, “Genomic approach for analysis of surface proteins in Chlamydia pneumoniae,” Infection and Immunity, vol. 70, no. 1, pp. 368–379, 2002. View at Publisher · View at Google Scholar · View at Scopus
6. T. M. Wizemann, J. H. Heinrichs, and J. H. Heinrichs, “Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection,” Infection and Immunity, vol. 69, no. 3, pp. 1593–1598, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
7. D. N. Chakravarti, M. J. Fiske, L. D. Fletcher, and R. J. Zagursky, “Application of genomics and proteomics for identification of bacterial gene products as potential vaccine candidates,” Vaccine, vol. 19, no. 6, pp. 601–612, 2000. View at Publisher · View at Google Scholar · View at Scopus
8. J. C. Betts, “Transcriptomics and proteomics: tools for the identification of novel drug targets and vaccine candidates for tuberculosis,” IUBMB Life, vol. 53, no. 4-5, pp. 239–242, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
9. A. S. De Groot, “Immunomics: discovering new targets for vaccines and therapeutics,” Drug Discovery Today, vol. 11, no. 5-6, pp. 203–209, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
10. J. L. Gardy, M. R. Laird, F. Chen, S. Rey, C. J. Walsh, M. Ester, and F. S. L. Brinkman, “PSORTb v.2.0: expanded prediction of bacterial protein subcellular localization and insights gained from comparative proteome analysis,” Bioinformatics, vol. 21, no. 5, pp. 617–623, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
11. L. Käll, A. Krogh, and E. L. Sonnhammer, “Advantages of combined transmembrane topology and signal peptide prediction—the Phobius web server,” Nucleic Acids Research, vol. 35, pp. W429–W432, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
12. G. Sachdeva, K. Kumar, P. Jain, and S. Ramachandran, “SPAAN: a software program for prediction of adhesins and adhesin-like proteins using neural networks,” Bioinformatics, vol. 21, no. 4, pp. 483–491, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
13. L. Li, C. J. Stoeckert Jr., and D. S. Roos, “OrthoMCL: identification of ortholog groups for eukaryotic genomes,” Genome Research, vol. 13, no. 9, pp. 2178–2189, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
14. S. Henikoff, J. G. Henikoff, and S. Pietrokovski, “Blocks+: a non-redundant database of protein alignment blocks derived from multiple compilations,” Bioinformatics, vol. 15, no. 6, pp. 471–479, 1999. View at Publisher · View at Google Scholar · View at Scopus
15. P. A. Reche, J.-P. Glutting, H. Zhang, and E. L. Reinherz, “Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles,” Immunogenetics, vol. 56, no. 6, pp. 405–419, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
16. B. Peters, H. H. Bui, and H. H. Bui, “A community resource benchmarking predictions of peptide binding to MHC-I molecules,” PLoS Computational Biology, vol. 2, no. 6 , article e65, 2006. View at Publisher · View at Google Scholar · View at PubMed
17. H.-G. Rammensee, J. Bachmann, N. P. N. Emmerich, O. A. Bachor, and S. Stevanović, “SYFPEITHI: database for MHC ligands and peptide motifs,” Immunogenetics, vol. 50, no. 3-4, pp. 213–219, 1999. View at Scopus
18. S. Vivona, F. Bernante, and F. Filippini, “NERVE: new enhanced reverse vaccinology environment,” BMC Biotechnology, vol. 6, article 35, 2006. View at Publisher · View at Google Scholar · View at PubMed
19. A. S. De Groot, H. Sbai, C. S. Aubin, J. McMurry, and W. Martin, “Immuno-informatics: mining genomes for vaccine components,” Immunology and Cell Biology, vol. 80, no. 3, pp. 255–269, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
20. C. DeLisi and J. A. Berzofsky, “T-cell antigenic sites tend to be amphipathic structures,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 20, pp. 7048–7052, 1985. View at Scopus
21. A. Sette, S. Buus, and S. Buus, “Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 86, no. 9, pp. 3296–3300, 1989. View at Scopus
22. O. Rotzschke, K. Falk, S. Stevanovic, G. Jung, P. Walden, and H.-G. Rammensee, “Exact prediction of a natural T cell epitope,” European Journal of Immunology, vol. 21, no. 11, pp. 2891–2894, 1991. View at Scopus
23. A. Sette, J. Sidney, and J. Sidney, “HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions,” Journal of Immunology, vol. 151, no. 6, pp. 3163–3170, 1993. View at Scopus
24. M. P. Davenport, I. A. P. H. Shon, and A. V. S. Hill, “An empirical method for the prediction of T-cell epitopes,” Immunogenetics, vol. 42, no. 5, pp. 392–397, 1995. View at Scopus
25. A. S. De Groot, B. M. Jesdale, E. Szu, J. R. Schafer, R. M. Chicz, and G. Deocampo, “An interactive web site providing major histocompatibility ligand predictions: application to HIV research,” AIDS Research and Human Retroviruses, vol. 13, no. 7, pp. 529–531, 1997. View at Scopus
26. V. Brusic, G. Rudy, and L. C. Harrison, “MHCPEP: a database of MHC-binding peptides,” Nucleic Acids Research, vol. 22, no. 17, pp. 3663–3665, 1994. View at Scopus
27. B. Peters, J. Sidney, and J. Sidney, “The immune epitope database and analysis resource: from vision to blueprint,” PLoS Biology, vol. 3, no. 3, article e91, pp. 379–381, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
28. M. S. Litwin, C. S. Saigal, and C. S. Saigal, “Urologic diseases in America project: analytical methods and principal findings,” Journal of Urology, vol. 173, no. 3, pp. 933–937, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
29. I. Connell, W. Agace, P. Klemm, M. Schembri, S. Mårild, and C. Svanborg, “Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9827–9832, 1996. View at Publisher · View at Google Scholar · View at Scopus
30. S. Langermann, R. Möllby, and R. Möllby, “Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli,” Journal of Infectious Diseases, vol. 181, no. 2, pp. 774–778, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
31. D. T. Uehling, W. J. Hopkins, J. E. Elkahwaji, D. M. Schmidt, and G. E. Leverson, “Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections,” Journal of Urology, vol. 170, no. 3, pp. 867–869, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. V. Kumar, N. K. Ganguly, K. Joshi, R. Mittal, K. Harjai, S. Chhibber, and S. Sharma, “Protective efficacy and immunogenicity of Escherichia coli K13 diphtheria toxoid conjugate against experimental ascending pyelonephritis,” Medical Microbiology and Immunology, vol. 194, no. 4, pp. 211–217, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
33. C. J. Alteri, E. C. Hagan, K. E. Sivick, S. N. Smith, and H. L. T. Mobley, “Mucosal immunization with iron receptor antigens protects against urinary tract infection,” PLoS Pathogens, vol. 5, no. 9, Article ID e1000586, 2009. View at Publisher · View at Google Scholar · View at PubMed
34. J. A. Snyder, B. J. Haugen, and B. J. Haugen, “Transcriptome of uropathogenic Escherichia coli during urinary tract infection,” Infection and Immunity, vol. 72, no. 11, pp. 6373–6381, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. C. J. Alteri and H. L. T. Mobley, “Quantitative profile of the uropathogenic Escherichia coli outer membrane proteome during growth in human urine,” Infection and Immunity, vol. 75, no. 6, pp. 2679–2688, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
36. E. C. Hagan and H. L. T. Mobley, “Uropathogenic Escherichia coli outer membrane antigens expressed during urinary tract infection,” Infection and Immunity, vol. 75, no. 8, pp. 3941–3949, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
37. Z. Xiang and Y. He, “Vaxign: a web-based vaccine target design program for reverse vaccinology,” Procedia in Vaccinology, vol. 1, no. 1, pp. 23–29, 2009. View at Publisher · View at Google Scholar · View at Scopus
38. H. R. Bigelow, D. S. Petrey, J. Liu, D. Przybylski, and B. Rost, “Predicting transmembrane beta-barrels in proteomes,” Nucleic Acids Research, vol. 32, no. 8, pp. 2566–2577, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
39. T. L. Bailey and M. Gribskov, “Combining evidence using p-values: application to sequence homology searches,” Bioinformatics, vol. 14, no. 1, pp. 48–54, 1998. View at Scopus
40. J. A. Swets, “Measuring the accuracy of diagnostic systems,” Science, vol. 240, no. 4857, pp. 1285–1293, 1988. View at Scopus
41. D. W. Huang, B. T. Sherman, and R. A. Lempicki, “Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources,” Nature Protocols, vol. 4, no. 1, pp. 44–57, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
42. K. D. Pruitt, T. Tatusova, and D. R. Maglott, “NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins,” Nucleic Acids Research, vol. 33, pp. D501–D504, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
43. F. R. Blattner, G. Plunkett III, and G. Plunkett, “The complete genome sequence of Escherichia coli K-12,” Science, vol. 277, no. 5331, pp. 1453–1462, 1997. View at Publisher · View at Google Scholar · View at Scopus
44. C. Wilson, H. Tiwana, and A. Ebringer, “Molecular mimicry between HLA-DR alleles associated with rheumatoid arthritis and Proteus mirabilis as the aetiological basis for autoimmunity,” Microbes and Infection, vol. 2, no. 12, pp. 1489–1496, 2000. View at Publisher · View at Google Scholar · View at Scopus
45. I. Nachamkin, B. M. Allos, and T. Ho, “Campylobacter species and Guillain-Barre syndrome,” Clinical Microbiology Reviews, vol. 11, no. 3, pp. 555–567, 1998. View at Scopus
46. C. A. Weber, P. J. Mehta, M. Ardito, L. Moise, B. Martin, and A. S. De Groot, “T cell epitope: friend or foe? Immunogenicity of biologics in context,” Advanced Drug Delivery Reviews, vol. 61, no. 11, pp. 965–976, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
47. P. Naves, G. del Prado, and G. del Prado, “Correlation between virulence factors and in vitro biofilm formation by Escherichia coli strains,” Microbial Pathogenesis, vol. 45, no. 2, pp. 86–91, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
48. D. Serruto, R. Rappuoli, and M. Pizza, “Meningococcus B: from genome to vaccine,” in Genomics, Proteomics and Vaccines, G. Grandi, Ed., pp. 185–201, John Wiley & Sons, 2004.
49. L. Durant, A. Metais, C. Soulama-Mouze, J.-M. Genevard, X. Nassif, and S. Escaich, “Identification of candidates for a subunit vaccine against extraintestinal pathogenic Escherichia coli,” Infection and Immunity, vol. 75, no. 4, pp. 1916–1925, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
50. A. G. Torres, P. Redford, R. A. Welch, and S. M. Payne, “TonB-dependent systems of uropathogenic Escherichia coli: aerobactin and heme transport and TonB are required for virulence in the mouse,” Infection and Immunity, vol. 69, no. 10, pp. 6179–6185, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
51. M. S. Walters and H. L. T. Mobley, “Identification of uropathogenic Escherichia coli surface proteins by shotgun proteomics,” Journal of Microbiological Methods, vol. 78, no. 2, pp. 131–135, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
52. S. Langermann, S. Palaszynski, and S. Palaszynski, “Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination,” Science, vol. 276, no. 5312, pp. 607–611, 1997. View at Publisher · View at Google Scholar · View at Scopus
53. D. Choudhury, A. Thompson, V. Stojanoff, S. Langermann, J. Pinkner, S. J. Hultgren, and S. D. Knight, “X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli,” Science, vol. 285, no. 5430, pp. 1061–1066, 1999. View at Publisher · View at Google Scholar · View at Scopus
54. T. A. Russo, C. D. McFadden, U. B. Carlino-MacDonald, J. M. Beanan, R. Olson, and G. E. Wilding, “The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate,” Infection and Immunity, vol. 71, no. 12, pp. 7164–7169, 2003. View at Publisher · View at Google Scholar · View at Scopus
55. A. S. De Groot, L. Marcon, E. A. Bishop, D. Rivera, M. Kutzler, D. B. Weiner, and W. Martin, “HIV vaccine development by computer assisted design: the GAIA vaccine,” Vaccine, vol. 23, no. 17-18, pp. 2136–2148, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
56. T. Sturniolo, E. Bono, and E. Bono, “Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices,” Nature Biotechnology, vol. 17, no. 6, pp. 555–561, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
57. A. Hosmalin, M. Clerici, and M. Clerici, “An epitope in human immunodeficiency virus 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 6, pp. 2344–2348, 1990. View at Scopus
58. Z. Xiang, T. Todd, and T. Todd, “VIOLIN: vaccine investigation and online information network,” Nucleic Acids Research, vol. 36, no. 1, pp. D923–D928, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus